IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Lonza Signs Manufacturing Deal with Biopharma Firm

11:31 AM MDT | June 26, 2009

Lonza says it has signed a deal to produce therapeutic monoclonal antibody Anthim for biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ). Anthim, which is in late-stage development, can be used to treat anthrax infection. Lonza says it will provide process development services and manufacturing capacity, using its GS Gene Expression System, under the deal. Elusys develops antibody therapeutics for treatment of infectious disease. Elusys has been active in the development of bio-warfare countermeasures since 2001 and has worked with the U.S. government...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa